Articles by Daniel A. Ermann, MD
Daniel A. Ermann, MD, reviews a large Medicare Fee-for-Service analysis showing zanubrutinib was associated with longer real-world treatment duration, time to next treatment, and overall survival vs acalabrutinib and ibrutinib in older patients with first-line CLL.
Closing Thoughts & Future Directions
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss advancements in CLL treatment, highlighting pirtobrutinib's role and the potential of CAR T-cells and bispecific therapies.
Co-Management, Community Partnerships & Longitudinal Care
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss the role of MRD testing in CLL treatment, emphasizing personalized approaches and the importance of continuity in patient care.
Resistance Testing, Peripheral vs. Tissue Sampling, and Clinical Monitoring
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss the impact of real-world data on CLL treatment sequencing, highlighting survival outcomes and the importance of targeted therapies.
Broader Measures of Treatment Success & Venetoclax Retreatment
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Explore the latest insights on venetoclax retreatment effectiveness and its impact on patient outcomes in chronic lymphocytic leukemia therapy.
Comparative Data, Safety Profiles, and Sequencing with Pirtobrutinib and Other BTKs
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss the implications of recent studies on pirtobrutinib, comparing its efficacy and safety against other BTK inhibitors for CLL treatment.
The Rise of Pirtobrutinib and Its Clinical Implications in CLL
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss strategies for selecting second-line therapies in CLL, emphasizing treatment history, patient response, and genetic factors.
Time-Limited Therapy, MRD, and Treatment Discontinuation
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss the balance of safety, efficacy, and logistics in treatment choices, highlighting the evolving landscape of BTK inhibitors and patient preferences.
Managing Early Relapse of CLL & Treatment Selection After Frontline Therapy
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss the importance of patient-specific factors and preferences in selecting first-line treatments for CLL.
First-Line Therapy Decisions & Risk Stratification in CLL
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Experts discuss evolving treatment strategies for CLL, highlighting the balance between time-limited and continuous therapies for optimal patient outcomes.
Introductions & Framework for CLL Treatment
ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH Explore the evolving treatment landscape for Chronic Lymphocytic Leukemia, focusing on BTK and BCL2 inhibitor strategies and biomarker testing insights.
